Abstract:AIM:To investigate the differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats.METHODS:A high-performance liquid chromatographic method with an ODS column (150 mm x 4.6 mm ID) and a mobile phase of methanol-water (70:30) was used for racemic nimodipine assay. Another method with a Chiralcel OJ column (250 mm x 4.6 mm ID) and a mixture of n-haxane-ethanol (85:15) as mobile phase was used to determine its two enantiomers. Nimodipine was monitored at 236 nm wavelength.RESULTS:The linearity, recoveries and the detection limits of the methods were found to be suitable for the determinations. The average results of within-day and between-day RSDs were 5.64% and 7.85% respectively, the mean recovery was 97.66% for the concentration ranges studied. The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.h.L-1, respectively. The S-(-)-nimodipine concentration was 2.23 and 1.97 times as high as that of R-(+)-nimodipine in heart and in cerebrum respectively and there was almost only S-(-)-nimodipine in cerebellum. But R-(+)-nimodipine concentration was 1.57, 3.69 and 4.20 times as high as that of S-(-)-nimodipine in major excretion organs such as kidney, spleen and liver respectively.CONCLUSION:The experimental results obtained by using the achiral and chiral liquid chromatography showed that the differences between enantiomers were apparent for the pharmacokinetics in rat plasma, and very significant for the distributions in major target tissues: heart, cerebrum and cerebellum, and main elimination tissues: kidney, spleen and liver.

Comparison of the Pharmacokinetics Between the Two Injections of Nimodipine in Beagle

Study on Preparation of Levetiracetam Sodium Extended-release Tablet and It's Pharmacokinetics in Beagle Dogs

Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation

Effects of Intranasal Administration of Nimodipine on Cerebral Hemodynamics of Dogs.

Study on Pharmacokinetics and Bioavailability of Nimodipine Nanostructured Lipid Carrier in Rats

In vivo pharmacokinetics and distribution of nimodipine microemulsion injection in mice

Comparison of pharmacokinetics between paclitaxel emulsion for injection and paclitaxel injection in beagles

Determination and Pharmacokinetics of MN9202 in Beagle Dogs

Pharmacokinetics of Ginkgolide B Injection in Beagle Dogs

Plasma concentration of sibutramine hydrochloride in beagle dog assayed by LC-MS and study on its pharmacokinetics

Determination of M-nifedipine in Beagle Dogs by RP-HPLC

Study on Pharmacokinetics of Melatonin Orally Disintegrating Tablets and Common Tablets in Beagle Dogs

Pharmacokinetic Comparision in Absorption of Rhein in SD Rats and Beagle Dogs

Study on the Bioavailability and Pharmacokinetics of Guaiphenesin Sustained Release Tablets in Beagle Dogs

Pharmacokinetics of Nanoparticle-Docetaxel Injection in Beagle Dogs

Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs

Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs

Pharmacokinetic Interaction Between Amlodipine and Irbesartan in Beagle Dogs

Study of bioequivalence of veterinary drugs “Pinpramil” and “Milbemax” in dogs

Pharmacokinetics and bioequivalence of deferiprone extended-release tablets in Beagle dogs

Studies on Differences of Pharmacokinetic Behavior and Tissue Distribution of Nimodipine and Its Two Enantiomers in Rats Using Achiral and Chiral Liquid Chromatography.